AHB
HZNP

Abner Herrman & Brock’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Abner Herrman & Brock’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,280
Closed -$2.42M – 99
2022
Q2 		$2.42M Sell
30,280
-3,675
-11% -$348K 0.42% 44
2022
Q1 		$3.57M Buy
33,955
+13,050
+62% +$1.27M 0.5% 42
2021
Q4 		$2.25M Buy
+20,905
New +$2.28M 0.29% 49

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Abner Herrman & Brock's HZNP Position: Q3 2022 in Review

Abner Herrman & Brock sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 30,280 shares — an estimated $2.42M sold.

Abner Herrman & Brock first reported a position in HZNP in Q4 2021 and held it in 3 quarters. The position peaked at $3.57M in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Abner Herrman & Brock reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Abner Herrman & Brock sold 30,280 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $2.42M.
  • Abner Herrman & Brock first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 3 quarters.
  • Abner Herrman & Brock's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.57M in Q1 2022.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Abner Herrman & Brock's 13F filing for Q3 2022, filed 6 Oct 2022.